Item request has been placed!
×
Item request cannot be made.
×
Processing Request
New molecular entities: Tekturna.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Subject Terms:
- Subject Terms:
- Abstract:
The article reports on the approval of aliskiren, an oral renin inhibitor for the treatment of hypertension. Aliskiren is approved by the U.S. Food & Drug Administration on March 5, 2007 as monotherapy or in combination with other antihypertensive agents. The efficacy of aliskiren monotherapy has been tested in patients with mild-to-moderate hypertension for eight weeks in clinical trial. The starting dosage of aliskiren is recommended to be 150 milligrams per day.
No Comments.